Related Experiment Videos
The ideal nucleoside/nucleotide backbone.
1Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD 21287, USA. jgallant@jhmi.edu
Journal of Acquired Immune Deficiency Syndromes (1999)
|August 21, 2004
Summary
Selecting the right nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) backbone is crucial for effective HIV treatment. This review compares NRTI/NtRTI backbone performance and safety in highly active antiretroviral therapy (HAART) regimens for treatment-naive patients.
Area of Science:
- Infectious Diseases
- Virology
- Pharmacology
Background:
- Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) backbones are foundational components of highly active antiretroviral therapy (HAART) for HIV treatment.
- Optimal NRTI/NtRTI backbone selection is critical for regimen efficacy and patient outcomes, yet no single backbone is universally ideal.
Purpose of the Study:
- To review and compare the performance and safety of various NRTI/NtRTI backbones used in HAART regimens since 2000.
- To guide the selection of NRTI/NtRTI backbones and third agents for treatment-naive HIV patients based on clinical trial data.
Main Methods:
- Systematic review of clinical trial data published since 2000 focusing on NRTI/NtRTI backbone performance and safety.
- Comparative analysis of different NRTI/NtRTI backbones against an ideal profile and other regimen selection factors.
Main Results:
- Data indicate that while no single NRTI/NtRTI backbone is perfect, each offers distinct advantages in HAART regimens.
- Performance and safety profiles vary, influencing the choice of backbone for optimal patient outcomes in treatment-naive individuals.
Conclusions:
- NRTI/NtRTI backbone selection requires careful consideration of individual patient factors and regimen goals.
- Evidence-based strategies can optimize HAART regimen selection and improve outcomes for treatment-naive HIV patients outside of clinical trials.